Ryvu Therapeutics 주식 주식분석 | 주식가격 | 뉴스 | RVU.WA | PLSELVT00013 | A1JUH2

날짜	Ryvu Therapeutics 주식 가격
	53.10 undefined
	52.00 undefined
	52.60 undefined
	54.00 undefined
	53.50 undefined
	53.00 undefined
	53.20 undefined
	52.80 undefined
	51.90 undefined
	51.40 undefined
	51.10 undefined
	49.70 undefined
	48.90 undefined
	53.40 undefined
	53.60 undefined
	51.10 undefined
	52.00 undefined
	53.00 undefined
	52.50 undefined
	49.60 undefined

날짜	Ryvu Therapeutics 매출	Ryvu Therapeutics EBIT	Ryvu Therapeutics 이익
2026e	265.77 백만 undefined	26.01 백만 undefined	-22,754.26 undefined
2025e	272.4 백만 undefined	-72.87 백만 undefined	-72.86 백만 undefined
2024e	184.48 백만 undefined	-92.72 백만 undefined	-90.6 백만 undefined
2023	46.86 백만 undefined	-97.38 백만 undefined	-92.11 백만 undefined
2022	38.95 백만 undefined	-70.69 백만 undefined	-83.78 백만 undefined
2021	11.19 백만 undefined	-78.89 백만 undefined	-79.08 백만 undefined
2020	15.65 백만 undefined	-35.67 백만 undefined	-31.69 백만 undefined
2019	3.8 백만 undefined	-45.39 백만 undefined	285.64 백만 undefined
2018	77.21 백만 undefined	-13.62 백만 undefined	-106,320 undefined
2017	67.54 백만 undefined	12.66 백만 undefined	6.41 백만 undefined
2016	48.13 백만 undefined	-1.22 백만 undefined	2.72 백만 undefined
2015	41.03 백만 undefined	2.07 백만 undefined	6.27 백만 undefined
2014	28.86 백만 undefined	5.27 백만 undefined	5.85 백만 undefined
2013	13.05 백만 undefined	-2.23 백만 undefined	-2.45 백만 undefined
2012	9.51 백만 undefined	-6.12 백만 undefined	-5.55 백만 undefined

	매출	EBIT	이익
2012	9.51 백만 PLN	-6.12 백만 PLN	-5.55 백만 PLN
2013	13.05 백만 PLN	-2.23 백만 PLN	-2.45 백만 PLN
2014	28.86 백만 PLN	5.27 백만 PLN	5.85 백만 PLN
2015	41.03 백만 PLN	2.07 백만 PLN	6.27 백만 PLN
2016	48.13 백만 PLN	-1.22 백만 PLN	2.72 백만 PLN
2017	67.54 백만 PLN	12.66 백만 PLN	6.41 백만 PLN
2018	77.21 백만 PLN	-13.62 백만 PLN	-106,320 PLN
2019	3.8 백만 PLN	-45.39 백만 PLN	285.64 백만 PLN
2020	15.65 백만 PLN	-35.67 백만 PLN	-31.69 백만 PLN
2021	11.19 백만 PLN	-78.89 백만 PLN	-79.08 백만 PLN
2022	38.95 백만 PLN	-70.69 백만 PLN	-83.78 백만 PLN
2023	46.86 백만 PLN	-97.38 백만 PLN	-92.11 백만 PLN
2024e	184.48 백만 PLN	-92.72 백만 PLN	-90.6 백만 PLN
2025e	272.4 백만 PLN	-72.87 백만 PLN	-72.86 백만 PLN
2026e	265.77 백만 PLN	26.01 백만 PLN	-22,754.26 PLN

2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
9	13	28	41	48	67	77	3	15	11	38	46	184	272	265
-	44.44	115.38	46.43	17.07	39.58	14.93	-96.10	400.00	-26.67	245.45	21.05	300.00	47.83	-2.57
11.11	23.08	50.00	70.73	70.83	61.19	66.23	-300.00	40.00	-227.27	-	43.48	-	-	-
1	3	14	29	34	41	51	-9	6	-25	0	20	0	0	0
-6	-2	5	2	-1	12	-13	-45	-35	-78	-70	-97	-92	-72	26
-66.67	-15.38	17.86	4.88	-2.08	17.91	-16.88	-1,500.00	-233.33	-709.09	-184.21	-210.87	-50.00	-26.47	9.81
-5	-2	5	6	2	6	0	285	-31	-79	-83	-92	-90	-72	0
-	-60.00	-350.00	20.00	-66.67	200.00	-	-	-110.88	154.84	5.06	10.84	-2.17	-20.00	-
10.46	10.46	10.46	13.05	13.74	13.77	15.52	15.97	16.77	18.36	18.36	22.9	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023

5.2	0	4.9	28.81	29.09	36.12	110.37	72.11	161.19	88.23	345.41	233.67
1.2	0	7	13.08	10.43	10	14.37	1.79	2.2	5.94	1.05	9.19
1.8	0	3.3	4.88	5.95	9.76	44	13.39	5.75	5.8	15.89	23.65
0.4	0	0.7	1.17	1.4	1.59	1.99	1.59	1.68	1.96	1.76	2.12
0.2	0	1.4	0.58	0.79	2.39	2.49	1.11	1.55	2.32	3.83	9.77
8.8	0	17.3	48.52	47.67	59.87	173.22	89.98	172.36	104.25	367.93	278.39
5.4	0	6.8	8.6	21.83	31.38	52.44	66.19	91.16	91.18	82.22	77.56
0.2	0	0	0	3.12	2.04	22.83	23.75	29.12	29.4	20.48	23.44
0	0	0	0	0	0	0	0	0	5.8	258.85	0
0	0	0.1	1.99	6.36	2.36	2.4	2.92	2.32	3.04	4.28	6.34
300	0	300	280.74	280.74	280.74	280.74	0	0	0	0	0
1.9	0	2.3	5.85	9.86	7.65	4.53	0.79	0.68	0.93	0.08	17.48
7.8	0	9.5	16.72	41.45	43.7	82.48	93.65	123.28	130.37	365.9	124.81
16.6	0	26.8	65.24	89.12	103.57	255.7	183.63	295.64	234.61	733.83	403.2

4.2	0	4.2	5.25	5.38	5.51	6.39	6.39	7.34	7.34	7.34	9.25
0	0	0	25.28	25.48	25.48	154.7	145.19	279.06	279.06	279.06	519.75
1.7	0	5.1	15.92	24.56	31.2	30.61	289.98	258.29	195.87	377.96	65.99
0	0	0	-2.62	-42.63	110.07	211.73	-320,977.45	-320,977.45	-320,977	-320,979	-335,395
0	0	0	0	0	0	0	0	0	0	0	0
5.9	0	9.3	46.45	55.37	62.3	191.91	120.58	223.72	161.3	343.39	259.59
1.9	0	5.4	3.91	6.79	9.37	16.36	21.61	10.86	14.19	14.45	25.35
1.5	0	0.7	2.45	3.94	1.51	2.64	3.41	5.31	4.86	11.7	12.22
4.1	0	8.8	9.67	6.4	14.06	13.13	2.3	14.56	14.41	16.77	31.59
0	0	0	0	0	0	0	0	0	0	0	0
0.2	0	0.5	0.3	1.8	1.82	3.43	3.3	3.08	2.75	1.9	0.54
7.7	0	15.4	16.32	18.93	26.75	35.57	30.62	33.81	36.2	44.81	69.7
0.3	0	0.2	0.3	7.82	6.17	10.04	5.92	4.33	2.32	0.87	9.22
0.1	0	0.1	0.17	0.21	0.53	4.57	5.14	6.04	0.44	0	0
2.5	0	2	1.57	6.44	6.13	10.66	21.37	27.74	28.56	85.91	64.69
2.9	0	2.3	2.04	14.48	12.83	25.27	32.43	38.11	31.31	86.77	73.91
10.6	0	17.7	18.36	33.41	39.58	60.84	63.05	71.92	67.51	131.59	143.61
16.5	0	27	64.81	88.78	101.88	252.75	183.63	295.64	228.81	474.98	403.2

2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
-5	-2	5	6	2	6	0	285	-31	-79	-83	-92
1	2	2	3	3	5	8	7	12	12	12	10
0	0	0	0	0	0	0	0	0	-5	0	0
-5	-6	-13	-25	-13	-2	-31	20	13	-9	61	-14
0	0	0	0	1	1	-14	-331	-5	22	31	10
0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	5	0
-9	-7	-4	-16	-6	10	-36	-17	-10	-58	21	-84
-2	-2	-3	-5	-21	-21	-23	-23	-34	-11	-9	-201
-2	-2	-3	-4	-18	-21	-37	-2	-55	8	0	-195
0	0	0	0	2	0	-13	21	-21	20	9	5
0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	4	-2	-2	-2	-3	-3	-2	-1
0	0	0	27	0	0	134	0	143	0	0	-7
9	9	7	45	24	17	147	-2	130	-2	-2	240
9	9	8	18	19	18	16	0	-8	0	0	250
0	0	0	0	0	0	0	0	0	0	0	0
-2	0	0	24	0	7	74	-22	64	-52	18	-43
-11.59	-9.37	-8.51	-21.62	-27.49	-10.58	-59.86	-41.4	-44.82	-70.87	12.03	-285.74
0	0	0	0	0	0	0	0	0	0	0	0

Ryvu Therapeutics 브루토마진	Ryvu Therapeutics 이익 마진	Ryvu Therapeutics EBIT-마진	Ryvu Therapeutics 이익 마진
2026e	44.8 %	9.79 %	-0.01 %
2025e	44.8 %	-26.75 %	-26.75 %
2024e	44.8 %	-50.26 %	-49.11 %
2023	44.8 %	-207.8 %	-196.57 %
2022	-1.65 %	-181.5 %	-215.12 %
2021	-228.3 %	-705.21 %	-706.94 %
2020	44 %	-227.92 %	-202.47 %
2019	-237.09 %	-1,194.87 %	7,520.15 %
2018	67.15 %	-17.64 %	-0.14 %
2017	61.61 %	18.75 %	9.49 %
2016	72.26 %	-2.54 %	5.65 %
2015	71.79 %	5.05 %	15.28 %
2014	51.06 %	18.26 %	20.27 %
2013	28.2 %	-17.09 %	-18.77 %
2012	12.93 %	-64.35 %	-58.36 %

	브루토마진	EBIT-마진	이익 마진
2012	12.93 %	-64.35 %	-58.36 %
2013	28.2 %	-17.09 %	-18.77 %
2014	51.06 %	18.26 %	20.27 %
2015	71.79 %	5.05 %	15.28 %
2016	72.26 %	-2.54 %	5.65 %
2017	61.61 %	18.75 %	9.49 %
2018	67.15 %	-17.64 %	-0.14 %
2019	-237.09 %	-1,194.87 %	7,520.15 %
2020	44 %	-227.92 %	-202.47 %
2021	-228.3 %	-705.21 %	-706.94 %
2022	-1.65 %	-181.5 %	-215.12 %
2023	44.8 %	-207.8 %	-196.57 %
2024e	44.8 %	-50.26 %	-49.11 %
2025e	44.8 %	-26.75 %	-26.75 %
2026e	44.8 %	9.79 %	-0.01 %

날짜	Ryvu Therapeutics 주당 매출	Ryvu Therapeutics EBIT 당 주식	Ryvu Therapeutics 주당 이익
2026e	11.5 undefined	0 undefined	-0 undefined
2025e	11.78 undefined	0 undefined	-3.15 undefined
2024e	7.98 undefined	0 undefined	-3.92 undefined
2023	2.05 undefined	-4.25 undefined	-4.02 undefined
2022	2.12 undefined	-3.85 undefined	-4.56 undefined
2021	0.61 undefined	-4.3 undefined	-4.31 undefined
2020	0.93 undefined	-2.13 undefined	-1.89 undefined
2019	0.24 undefined	-2.84 undefined	17.88 undefined
2018	4.97 undefined	-0.88 undefined	-0.01 undefined
2017	4.9 undefined	0.92 undefined	0.47 undefined
2016	3.5 undefined	-0.09 undefined	0.2 undefined
2015	3.14 undefined	0.16 undefined	0.48 undefined
2014	2.76 undefined	0.5 undefined	0.56 undefined
2013	1.25 undefined	-0.21 undefined	-0.23 undefined
2012	0.91 undefined	-0.59 undefined	-0.53 undefined

	주당 매출	EBIT 당 주식	주당 이익
2012	0.91 PLN	-0.59 PLN	-0.53 PLN
2013	1.25 PLN	-0.21 PLN	-0.23 PLN
2014	2.76 PLN	0.5 PLN	0.56 PLN
2015	3.14 PLN	0.16 PLN	0.48 PLN
2016	3.5 PLN	-0.09 PLN	0.2 PLN
2017	4.9 PLN	0.92 PLN	0.47 PLN
2018	4.97 PLN	-0.88 PLN	-0.01 PLN
2019	0.24 PLN	-2.84 PLN	17.88 PLN
2020	0.93 PLN	-2.13 PLN	-1.89 PLN
2021	0.61 PLN	-4.3 PLN	-4.31 PLN
2022	2.12 PLN	-3.85 PLN	-4.56 PLN
2023	2.05 PLN	-4.25 PLN	-4.02 PLN
2024e	7.98 PLN	0 PLN	-3.92 PLN
2025e	11.78 PLN	0 PLN	-3.15 PLN
2026e	11.5 PLN	0 PLN	-0 PLN

	주식 수량
2012	10.46 백만 Aktien
2013	10.46 백만 Aktien
2014	10.46 백만 Aktien
2015	13.05 백만 Aktien
2016	13.74 백만 Aktien
2017	13.77 백만 Aktien
2018	15.52 백만 Aktien
2019	15.97 백만 Aktien
2020	16.77 백만 Aktien
2021	18.36 백만 Aktien
2022	18.36 백만 Aktien
2023	22.9 백만 Aktien
2024e	22.9 백만 Aktien
2025e	22.9 백만 Aktien
2026e	22.9 백만 Aktien

%-지분	이름	주식	변경
8.29 %	BioNTech SE	1,917,437	0
8.22 %	Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SA	1,900,000	0
5.94 %	FORUM Towarzystwo Funduszy Inwestycyjnych S.A.	1,372,713	0
5.94 %	Wesolowski (Tadeusz)	1,372,713	1,372,713
3.57 %	Sieczkowski (Boguslaw Stanislaw)	825,348	0
2.06 %	Norges Bank Investment Management (NBIM)	476,148	112,450
17.48 %	Towarzystwo Funduszy Inwestycyjnych Allianz Polska SA	4,042,236	0
17.45 %	Przewiezlikowski (Pawel)	4,033,286	-31,750
0.63 %	ESALIENS TFI SA	146,762	30,781
0.62 %	UNIQA Towarzystwo Funduszy Inwestycyjnych S. A	142,524	25,637
0.52 %	Pekao Towarzystwo Funduszy Inwestycyjnych SA	120,906	54,213
0.48 %	Skarbiec Towarzystwo Funduszy Inwestycyjnych S.A.	110,549	0
0.36 %	PZU Asset Management SA	83,700	25,269
0.32 %	Rockbridge Towarzystwo Funduszy Inwestycyjnych S.A.	73,336	9,181
0.24 %	Towarzystwo Funduszy Inwestycyjnych PZU SA	55,520	39,000
0.18 %	Generali Investments Towarzystwo Funduszy Inwestycyjnych S.A	41,528	-7,364
0.04 %	Towarzystwo Funduszy Inwestycyjnych BNP Paribas Polska S.A.	9,559	1,004
0.00 %	State Street Global Advisors (US)	189	33
0 %	Superfund Towarzystwo Funduszy Inwestycyjnych S.A.	0	-4,899
0 %	Alphajet Fair Investors, SAS	0	-5,000

What values and corporate philosophy does Ryvu Therapeutics represent?

Ryvu Therapeutics SA is a biotechnology company that is committed to transforming patient care and addressing unmet medical needs. The company's corporate philosophy revolves around innovation, scientific excellence, and a patient-centric approach. Ryvu Therapeutics SA values the power of collaboration and partnerships, aiming to drive advancements in the field of oncology and rare diseases. With a focus on research and development, Ryvu Therapeutics SA strives to bring novel therapies to the market that have the potential to significantly improve and extend the lives of patients. This dedication to scientific discovery and a result-driven mindset defines the core values of Ryvu Therapeutics SA.

In which countries and regions is Ryvu Therapeutics primarily present?

Ryvu Therapeutics SA is primarily present in Poland, where it is headquartered.

What significant milestones has the company Ryvu Therapeutics achieved?

Ryvu Therapeutics SA has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in February 2019, raising funds to support its research and development efforts. In October 2019, Ryvu Therapeutics SA entered into a collaboration agreement with an international pharmaceutical company for the development of innovative cancer therapies. Another noteworthy achievement is the advancement of its internal pipeline, particularly the progress made in the clinical development of its investigational drug candidates. These achievements demonstrate Ryvu Therapeutics SA's commitment to advancing novel therapies and establishing strategic partnerships in the field of oncology.

What is the history and background of the company Ryvu Therapeutics?

Ryvu Therapeutics SA is a biopharmaceutical company founded in 2007 in Poland. It focuses on discovering and developing innovative small molecule therapies for the treatment of various cancers. Ryvu Therapeutics SA has a strong research and development pipeline, with a particular emphasis on targeted therapies that can potentially address the underlying mechanisms driving cancer growth. The company has made significant progress in preclinical and early clinical stages, with several promising drug candidates. Ryvu Therapeutics SA aims to improve patient outcomes and contribute to the advancement of cancer treatment through its dedication to scientific excellence and innovative drug development approaches.

Who are the main competitors of Ryvu Therapeutics in the market?

The main competitors of Ryvu Therapeutics SA in the market include Genmab A/S, Incyte Corporation, and Gilead Sciences, Inc. These companies are also active in the biopharmaceutical industry, focusing on developing and commercializing innovative therapies. However, Ryvu Therapeutics SA brings unique offerings to the market with its portfolio of proprietary drug candidates and therapeutic platforms. With its commitment to advancing precision oncology and targeted therapies, Ryvu Therapeutics SA distinguishes itself from its competitors and aims to make a significant impact in the field of biopharmaceuticals.

In which industries is Ryvu Therapeutics primarily active?

Ryvu Therapeutics SA is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Ryvu Therapeutics?

Ryvu Therapeutics SA operates under a business model focused on developing innovative therapies to address unmet medical needs. They specialize in research and development of novel small molecule drugs targeting cancer and inflammatory diseases. As a biopharmaceutical company, Ryvu Therapeutics is dedicated to discovering and advancing potential treatments through rigorous scientific methods. By leveraging their expertise in drug discovery and understanding of disease biology, they strive to deliver breakthrough medicines that can improve patient outcomes. Ryvu Therapeutics aims to bring innovative therapies to market that have the potential to transform patient care in areas where medical needs are not yet met.

Ryvu Therapeutics 2024의 P/E 비율은 얼마입니까?

Ryvu Therapeutics의 P/E 비율은 -13.42입니다.

Ryvu Therapeutics 2024의 KUV는 얼마입니까?

Ryvu Therapeutics의 P/S 비율은 6.59입니다.

Ryvu Therapeutics의 AlleAktien 품질 점수는 얼마인가요?

Ryvu Therapeutics에 대한 AlleAktien 품질 점수는 6/10입니다.

Ryvu Therapeutics 2024의 매출은 얼마인가요?

예상되는 Ryvu Therapeutics 매출은 184.48 백만 PLN입니다.

Ryvu Therapeutics 2024의 이익은 얼마인가요?

예상되는 Ryvu Therapeutics 이익은 -90.6 백만 PLN입니다.

Ryvu Therapeutics은 무엇을 하나요?

Ryvu Therapeutics SA is a research-driven biotechnology company focused on developing novel therapies for cancer and inflammatory diseases. The company collaborates closely with researchers and academics to make breakthrough discoveries in oncology research and translate them into clinical applications. The business model of Ryvu Therapeutics SA is based on combining innovative research with numerous partnerships with academic institutions to develop novel drugs that can be used against cancer and inflammatory diseases. The company's goal is to improve the lives of cancer patients and expand the boundaries of medicine through the development of innovative technologies and new treatment options. To achieve this, the company has a wide range of products in the pipeline, including small molecule inhibitors, biologics, and immunotherapies. In addition to developing new treatment options, Ryvu Therapeutics SA also works closely with academic institutions to make new discoveries in oncology research and translate them into clinical applications. The company aims to attract new partners and investors to expand its business model and venture into new therapy areas. Overall, Ryvu Therapeutics SA's business model offers a wide range of products and services tailored to the needs of cancer patients. The company combines innovative research with numerous partnerships with academic institutions to make groundbreaking discoveries in oncology research and translate them into clinical applications. With a wide range of products in the pipeline and a dedicated leadership team, Ryvu Therapeutics SA is well positioned to improve the lives of cancer patients and promote the growth of the company.

Ryvu Therapeutics 배당금은 얼마입니까?

Ryvu Therapeutics은(는) 연간 번의 배당을 통해 0 PLN의 배당금을 지급합니다.

Ryvu Therapeutics이 얼마나 자주 배당을 지급하나요?

Ryvu Therapeutics의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Ryvu Therapeutics ISIN이 무엇입니까?

Ryvu Therapeutics의 ISIN은 PLSELVT00013입니다.

Ryvu Therapeutics WKN은 무엇인가요?

Ryvu Therapeutics의 WKN은 A1JUH2입니다.

Ryvu Therapeutics 티커는 무엇인가요?

Ryvu Therapeutics의 티커는 RVU.WA입니다.

Ryvu Therapeutics이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 Ryvu Therapeutics은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Ryvu Therapeutics은(는) 0 PLN의 배당금을 지급할 것으로 예상됩니다.

Ryvu Therapeutics의 배당 수익률은 얼마입니까?

Ryvu Therapeutics의 현재 배당 수익률은 입니다.

Ryvu Therapeutics의 배당금은 언제 지급되나요?

Ryvu Therapeutics은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Ryvu Therapeutics의 배당금은 얼마나 안전한가요?

Ryvu Therapeutics은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

Ryvu Therapeutics의 배당금은 얼마입니까?

향후 12개월 동안 0 PLN의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Ryvu Therapeutics이(가) 속해 있는 섹터는 어디인가요?

Ryvu Therapeutics은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von Ryvu Therapeutics kaufen, um die vorherige Dividende zu erhalten?

Ryvu Therapeutics의 마지막 배당금을 0 PLN만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

Ryvu Therapeutics의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

Ryvu Therapeutics의 2023년도 배당금은 얼마였습니까?

2023년에 Ryvu Therapeutics는 0 PLN를 배당금으로 지급했습니다.

Ryvu Therapeutics는 어떤 화폐로 배당금을 지급하나요?

Ryvu Therapeutics의 배당금은 PLN에 지급됩니다.

증권거래소	Ryvu Therapeutics 티커
프랑크푸르트	9Y4.F
LONDON	0RKT.L
바르샤바	RVU.WA
WSE	SLV.WA

Ryvu Therapeutics 티커	Ryvu Therapeutics FIGI
SLV3EUR:XG	BBG00ZJ0LLX5
RVU:PW	BBG001VBZ2F9
SLVPLN:EO	BBG007TGWS00
SLVPLN:XH	BBG007TGWS37
SLVPLN:XF	BBG007TGWS55
SLVPLN:XE	BBG007TGWS73
SLVPLN:XJ	BBG007TGWS82
SLVPLN:XL	BBG007TGWS91
SLVPLN:XG	BBG007TGWSB8
SLVPLN:XO	BBG007TGWSC7
SLVPLN:XS	BBG007TGWSH2
SLVPLN:XA	BBG007TGWSJ0
SLVPLN:E1	BBG007TGWSK8
SLVPLN:XT	BBG007TGWSL7
SLVPLN:XW	BBG007TGWSM6
SLVPLN:XU	BBG007TGWSN5
SLVPLN:XV	BBG007TGWSQ2
SLVPLN:EU	BBG007TGWSS0
RYVUW:B3	BBG007WWX5V6
RYVUW:L3	BBG007WX0HB6
RYVUW:PO	BBG008H0J324
0RKT:LN	BBG00JHW7QN9
SLVPLN:XX	BBG00JN89SX8
RVUW:L1	BBG00Y92SJL6
9Y4:GR	BBG00ZHRJLL4
9Y4:GF	BBG00ZHRJLM3
9Y4:GS	BBG00ZHRJLQ9
SLV3EUR:XS	BBG00ZJ0LLL8
SLV3EUR:XH	BBG00ZJ0LLP4
SLV3EUR:XF	BBG00ZJ0LLR2
SLV3EUR:XE	BBG00ZJ0LLT0
SLV3EUR:XL	BBG00ZJ0LLW6
SLV3EUR:XO	BBG00ZJ0LLY4
SLV3EUR:XA	BBG00ZJ0LM27
SLV3EUR:XT	BBG00ZJ0LM45
SLV3EUR:XW	BBG00ZJ0LM54
SLV3EUR:XU	BBG00ZJ0LM63
SLV3EUR:XV	BBG00ZJ0LM81
SLV3EUR:XM	BBG00ZJ0LM90
SLV3EUR:EU	BBG00ZJ0LMJ9

한 눈에 저평가된 주식을 인식하세요 fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

가격

가격

티커RVU.WA

ISINPLSELVT00013

WKNA1JUH2

Ryvu Therapeutics 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

Ryvu Therapeutics 주가 이력

Ryvu Therapeutics 주식 매출, EBIT, 이익 PLSELVT00013 · A1JUH2

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

Ryvu Therapeutics 매출, 이익 및 EBIT 역사

Ryvu Therapeutics 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

Ryvu Therapeutics 주식 마진 PLSELVT00013 · A1JUH2

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

Ryvu Therapeutics 마진 역사

Ryvu Therapeutics 주식 매출, EBIT, 주당 순이익 PLSELVT00013 · A1JUH2

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Ryvu Therapeutics 매출, 이익 및 EBIT 주당 역사

Ryvu Therapeutics 주식 및 주식 분석

Ryvu Therapeutics Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

Ryvu Therapeutics 역사적인 P/E, EBIT 및 P/S에 따른 평가

Ryvu Therapeutics 주식 수량 PLSELVT00013 · A1JUH2

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

Ryvu Therapeutics 수익 예상

Ryvu Therapeutics 수익 놀라움

Ryvu Therapeutics 주식 주주 구조

Ryvu Therapeutics 임원진 및 경영진

Ryvu Therapeutics 주식에 대한 자주 묻는 질문

What values and corporate philosophy does Ryvu Therapeutics represent?

In which countries and regions is Ryvu Therapeutics primarily present?

What significant milestones has the company Ryvu Therapeutics achieved?

What is the history and background of the company Ryvu Therapeutics?

Who are the main competitors of Ryvu Therapeutics in the market?

In which industries is Ryvu Therapeutics primarily active?

What is the business model of Ryvu Therapeutics?

Ryvu Therapeutics 2024의 P/E 비율은 얼마입니까?

한 눈에 저평가된 주식을 인식하세요
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

티커
RVU.WA

ISIN
PLSELVT00013

WKN
A1JUH2